$0.86
0.0019[0.22%]
At close: Apr 16
$0.86
0[0.00%]
After Hours: 4:37PM EDT
Gossamer Bio
(NASDAQ:GOSS)Gossamer Bio Stock (NASDAQ:GOSS), Analyst Ratings, Price Targets, Predictions
Gossamer Bio Inc has a consensus price target of $6.75, established from looking at the 39 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, Piper Sandler, and Goldman Sachs on April 5, 2024, March 27, 2024, and March 6, 2024. With an average price target of $9 between Wedbush, Piper Sandler, and Goldman Sachs, there's an implied 946.51% upside for Gossamer Bio Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Piper Sandler
Goldman Sachs
Wedbush
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Gossamer Bio
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/05/2024 | GOSS | Buy Now | Gossamer Bio | $0.86 | 365.12% | Wedbush | Laura Chico | → $4 | Assumes | → Outperform | Get Alert |
| 03/27/2024 | GOSS | Buy Now | Gossamer Bio | $0.86 | 1644.19% | Piper Sandler | Yasmeen Rahimi | → $15 | Maintains | Overweight | Get Alert |
| 03/06/2024 | GOSS | Buy Now | Gossamer Bio | $0.86 | 830.23% | Goldman Sachs | Paul Choi | $9 → $8 | Maintains | Buy | Get Alert |
| 03/06/2024 | GOSS | Buy Now | Gossamer Bio | $0.86 | 597.67% | Wedbush | Andreas Argyrides | → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | GOSS | Buy Now | Gossamer Bio | $0.86 | 1062.79% | HC Wainwright & Co. | Patrick Trucchio | → $10 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2024 | GOSS | Buy Now | Gossamer Bio | $0.86 | 1062.79% | HC Wainwright & Co. | Patrick Trucchio | $5 → $10 | Maintains | Buy | Get Alert |
| 12/19/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 597.67% | Wedbush | Andreas Argyrides | → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 11/10/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 597.67% | Wedbush | Andreas Argyrides | $5 → $6 | Maintains | Outperform | Get Alert |
| 08/11/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 481.4% | Wedbush | Andreas Argyrides | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 481.4% | HC Wainwright & Co. | Patrick Trucchio | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 481.4% | Wedbush | Andreas Argyrides | $7 → $5 | Maintains | Outperform | Get Alert |
| 07/26/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 481.4% | HC Wainwright & Co. | Patrick Trucchio | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 713.95% | Wedbush | Andreas Argyrides | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 05/11/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 481.4% | HC Wainwright & Co. | Patrick Trucchio | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 74.42% | Barclays | Carter Gould | $2 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 03/07/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | 481.4% | Raymond James | — | → $5 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/01/2023 | GOSS | Buy Now | Gossamer Bio | $0.86 | — | Guggenheim | Vamil Divan | — | Initiates | → Neutral | Get Alert |
| 12/08/2022 | GOSS | Buy Now | Gossamer Bio | $0.86 | 481.4% | HC Wainwright & Co. | Patrick Trucchio | $25 → $5 | Maintains | Buy | Get Alert |
| 12/07/2022 | GOSS | Buy Now | Gossamer Bio | $0.86 | 1062.79% | Goldman Sachs | Paul Choi | $22 → $10 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Gossamer Bio (GOSS)?
The latest price target for Gossamer Bio (NASDAQ: GOSS) was reported by Wedbush on April 5, 2024. The analyst firm set a price target for $4.00 expecting GOSS to rise to within 12 months (a possible 365.12% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gossamer Bio (GOSS)?
The latest analyst rating for Gossamer Bio (NASDAQ: GOSS) was provided by Wedbush, and Gossamer Bio their outperform rating.
When was the last upgrade for Gossamer Bio (GOSS)?
There is no last upgrade for Gossamer Bio.
When was the last downgrade for Gossamer Bio (GOSS)?
The last downgrade for Gossamer Bio Inc happened on March 7, 2023 when Raymond James changed their price target from N/A to $5 for Gossamer Bio Inc.
When is the next analyst rating going to be posted or updated for Gossamer Bio (GOSS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gossamer Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gossamer Bio was filed on April 5, 2024 so you should expect the next rating to be made available sometime around April 5, 2025.
Is the Analyst Rating Gossamer Bio (GOSS) correct?
While ratings are subjective and will change, the latest Gossamer Bio (GOSS) rating was a with a price target of $0.00 to $4.00. The current price Gossamer Bio (GOSS) is trading at is $0.86, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.